From R&D to Application: Quality Control and Registration Challenges of Soluble Inflammatory Factor Detection Kits

Construction of Raw Material and Kit Systems in the R&D Stage

Soluble inflammatory factor detection kits belong to immunoassay products within in vitro diagnostic reagents, and their core raw materials include specific antibodies, recombinant antigens, calibrator matrices, and signal amplification systems. During R&D, antibody pairing must be screened for high specificity and low cross-reactivity, particularly for the ability to distinguish structurally similar factors (such as the interleukin family). Kits are generally required to be traceable to international or national reference standards, such as World Health Organization standards for related factors, to ensure metrological consistency of test results. In addition, the matrix used to prepare calibrators should be as consistent as possible with the clinical sample matrix (such as factor-depleted human serum) to reduce matrix effects.

Key Indicators in Performance Evaluation

According to requirements such as the Regulations on the Registration and Administration of In Vitro Diagnostic Reagents, soluble inflammatory factor detection kits must complete analytical performance evaluation, including sensitivity (limit of detection, limit of quantification), precision (within-run, between-run, and total precision), linear range, interference testing (common interferents such as bilirubin, hemoglobin, and lipids), and carryover rate. The establishment of reference intervals for clinical samples should include at least 200 apparently healthy individuals and consider stratification by factors such as age, sex, and race; at the same time, the kit's ability to discriminate among populations with different inflammatory diseases should be validated, but terms such as "diagnostic accuracy" and "" must not be used as promotional language. Clinical trials must be conducted at at least two medical institutions, comparing with reference methods or marketed similar reagents.

Common Non-compliance Risk Points in Registration Applications

Some developers use suggestive descriptions such as "early detection" and "precise assessment of inflammation severity" in product instructions, posing a risk of exceeding the scope of the registration certificate. According to regulations, the intended use of the kit must be limited to "adjunctive diagnosis" or "monitoring," and it must not directly claim "diagnosis." The section of the instructions explaining test results should clearly state that they are for reference only and must be combined with clinical symptoms. In addition, absolute terms such as "best," "only," and "" are strictly prohibited in kit labels and promotional materials. Information such as storage conditions, shelf life, and lot number on the packaging must be consistent with actual validation data.

Quality Control and User Education in Clinical Application

When soluble inflammatory factor detection kits are used in end laboratories, a regular quality control plan must be established, including using commercial quality control materials for internal quality control and participating in external quality assessment programs. Because minor differences between different kit lots may affect the consistency of long-term monitoring results, kit manufacturers should provide lot-to-lot variation validation data and recommend that laboratories perform parallel comparisons when changing lot numbers. User training should focus on sample handling specifications, principles of result interpretation, and kit limitations; for example, some factors show transient increases during acute infection and must be judged in combination with sampling time points.

Future Trends: Standardization and Multi-scenario Adaptation

As demand for soluble inflammatory factor detection kits increases in fields such as critical care medicine, infectious diseases, and tumor immunotherapy, the industry is promoting standardization work for more factors (such as the combined application of IL-6, CRP, and procalcitonin). New technologies such as microfluidics, chemiluminescence, and single-molecule immunoassays are continuously being incorporated into kit design, improving detection speed and sensitivity. At the same time, registration review requirements for clinical evaluation of kits are becoming increasingly stringent, requiring more real-world data to support their applicability in different populations. R&D companies should continuously optimize kit performance within the compliance framework to meet clinical precision measurement needs.